Company intelligence / Profile preview

Celest Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

Celest is leading the clinical development of SN301A/SENTI‑301A, an off-the-shelf CAR-NK cell therapy targeting GPC3 in hepatocellular carcinoma. The first patient was dosed in a Phase I trial in China in December 2024. The trial aims to assess safety and preliminary anti-tumor activity; initial data are pending but the program represents one of the first applications of Senti Bio’s Gene Circuit technology in solid tumors through a partnership with Senti Biosciences[9][6].

Therapeutic areas: Oncology
Modalities: CAR-NK cell therapyCell therapyImmunotherapy
Industry: Biotech

Drug pipeline

2 assets

SUV2208A

1 more asset in the full pipeline.

Request access →

Partnerships

Senti Biosciences Inc.[1][5]

Beyond the preview

Go deeper on Celest Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celest Therapeutics.

Explore the full profile